Biological heterogeneity of primary and metastatic brain tumor in breast cancer patients
Year: 2021, volume 17 Issue: №4 Pages: 719-724
Heading: neurosurgery Article type: Original article
Authors: Subbotina D.R., Gulyaev D.A., Mitrofanova L.B.
Organization: North-West State Medical University n.a. I.I. Mechnikov, Department of Neuropathology Assistant Professor, Candidate of Medical Science, The Almazov National Medical Research Centre, Head of Second Cerebral and Spinal Cord Tumors Department, Doctor of Medical Sciences
Heading: neurosurgery Article type: Original article
Authors: Subbotina D.R., Gulyaev D.A., Mitrofanova L.B.
Organization: North-West State Medical University n.a. I.I. Mechnikov, Department of Neuropathology Assistant Professor, Candidate of Medical Science, The Almazov National Medical Research Centre, Head of Second Cerebral and Spinal Cord Tumors Department, Doctor of Medical Sciences
Summary:
Purpose: to evaluate the frequency of discordance of receptor status and HER2 status in primary and metastatic brain tumor in patients with breast cancer. Material and methods. The study included 18 patients whose brain metas-tases from breast cancer were treated surgically. An immunohistochemical assay of tumoral samples was performed to assess the expression of ER, PR, HER2. The results obtained were compared in pairs with samples from primary tumors. Results. The receptor status of the primary tumor and brain metastasis was constant in 50% of patients, while discordance in HR status was detected in 44% of cases. The rarest receptor conversions were the acquisition of HER 2+ status at 6% (n=1) and the loss of HER 2+ status at 11 % (n=2). 67% of patients with HR+ primary breast tumors, receiving adjuvant anti-estrogen therapy lost expression of the target receptor in brain metastases. Conclusion. In half of the tumor pairs under study we detected discordance in at least one of the indicators (ER, PR, HER2) of tumor biological heterogeneity. Loss of HR+ status in metastatic tumor was observed more often than other morphological transformations.
Bibliography:
1. Timmer M, Werner JM, Rbhn G, et al. Discordance and conversion rates of progesterone-, estrogen-, and HER2/neu-re-ceptor status in primary breast cancer and brain metastasis mainly triggered by hormone therapy. Anticancer Res 2017; 37 (9): 4859-65.
2. Kolyadina IV, Andreeva YuYu, Frank GA, et al. Role of biological heterogeneity in recurrent and metastatic breast cancer. Archive of Pathology 2018; 80 (6): 62-7.
3. Bachmann С, Grischke Е М, Fehm Т, et al. CNS metas-tases of breast cancer show discordant immunohistochemical phenotype compared to primary. Clin Oncol 2013; (139): 551-6.
4. Shen Qi, Sahin AA, Hess KR, et al. Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis. Oncologist 2015; 20 (5): 466-73.
5. Joubert C, Boissonneau S, Fina F, et al. Immunohistochemical hormonal mismatch and human epidermal growth factor type 2 [HER2] phenotype ofbrain metastases in breast cancer carcinoma compared to primary. Neurochirurgie 2016; (62): 151-6.
6. Jung J, Lee SH, Park M, et al. Discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis. Journal of Neuro-Oncology 2018; 137 (2): 295-302.
7. Hulsbergen AFC, Claes A, Kavouridis VK, et al. Subtype switching in breast cancer brain metastases: a multicenter analysis. Neuro Oncol 2020; 22 (8): 1173-81.
8. Kao J-Y, Tsai J, Wu T, et al. Receptor discordance and phenotype change in metastatic breast cancer. Asian Journal of Surgery 2020; 44(1): 192-8.
9. Kotecha R, Tonse R, Rubens M, et al. Systematic review and meta-analysis of breast cancer brain metastasis and primary tumor receptor expression discordance. Neurooncol Adv 2021; 3(1): vdab010.
| Attachment | Size |
|---|---|
| 2021_04_719-724.pdf | 966.31 KB |
Русский
English